DRGEM Corporation (263690) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DRGEM Corporation stock KRW 12,649, price KRW 4,870, upside +159.7%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 4,750 KRW – 12,713 KRW · fair‑value band 8,560 KRW – 17,110 KRW · the 4,870 KRW price screens below the 12,649 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow DRGEM in your weekly email
Every Wednesday you see whether DRGEM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DRGEM Corporation manufactures and sells diagnostic radiography systems. It offers high frequency X-ray generators; conventional and digital radiography systems; and ACQUIDR, a digital imaging system. DRGEM Corporation exports its products.
Show moreShow less
The company was founded in 2003 and is headquartered in Gwangmyeong-si, South Korea.
Stock analysis
DRGEM Corporation (263690) currently trades at 4,870 KRW, while our model-based Fair Value estimate is 12,649 KRW, implying the stock looks roughly 62% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 14,085 KRW per share, and 21 of the 26 models we run sit above the 4,870 KRW price.
Bear case: the Dividend Discount group reads lowest at 2,810 KRW, and 5 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 8,560 KRW (bear) to 17,110 KRW (bull), the price of 4,870 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
DRGEM Corporation reported revenue of 103B KRW in FY2025 versus 85.8B KRW in FY2021, a compound +4.6%/yr. Reported net income was 6.8B KRW in FY2025, compounding −14.3%/yr from FY2021.
Key figures
Market cap 53.1B KRW (≈ $39.2M) Micro · P/E ratio 4.4 · P/S ratio 0.49 · EPS (TTM) 1,127 KRW · Dividend yield 3.7% · Net margin 11.2% · Return on equity 13.3% · Return on assets (EBIT) 10.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 160%, 263690 screens cheaper than that median.
Fair Value models
Bear8,560 KRWFair Value 12,649 KRWBull17,110 KRW
Price 4,870 KRW · Upside +159.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (813.79 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
Start year 2020 (pandemic). Over 10 years: +12.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.4%
Dividend (yield on the price)3.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−11.4% vs 33.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−12.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −14.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside+159.7% · Top 25%
Profitability
Return on equity (12 months)13.3% · Top 25%
Return on assets5.6% · Above median
Net margin (12 months)11.2% · Above median
Operating margin (12 months)11.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.0% · Above median
Dividend yield (12 months)3.7% · Top 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DRGEM Corporation Fair Value". https://www.fairvalue-calculator.com/stock/263690
Frequently asked questions
Is DRGEM Corporation (263690) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 12,649 KRW versus a price of 4,870 KRW, about +160% upside (undervalued).
What is the fair value of 263690?
Our model-based fair value for DRGEM Corporation is 12,649 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 4,870 KRW.
What is the quality score of 263690?
DRGEM Corporation has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DRGEM Corporation (263690)?
Our model-based price target is the fair value of 12,649 KRW (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 8,560 KRW, optimistic scenario 17,110 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DRGEM Corporation stock forecast for 2026?
Our models put fair value at 12,649 KRW, about +160% upside versus a price of 4,870 KRW (undervalued). Cautious scenario 8,560 KRW, optimistic scenario 17,110 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DRGEM Corporation (263690)?
DRGEM Corporation reported trailing-twelve-month revenue of about 109B KRW (latest available figure, as of Nov 9, 2026).
Does DRGEM Corporation pay a dividend?
DRGEM Corporation currently shows a dividend yield of 3.66% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of DRGEM Corporation (263690) and when is the ex-dividend date?
DRGEM Corporation pays a dividend of 178.00 KRW per share a year, a dividend yield of 3.7%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2018. The payout ratio is 15.8% of earnings. Free cash flow covers the dividend 3.72 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into DRGEM Corporation (263690)?
For today's price to be fair in a discounted-cash-flow model, DRGEM Corporation would have to grow free cash flow by -12.7 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.7 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 263690 use?
Our models discount DRGEM Corporation at 8.9 %: a base by market capitalisation (nano), damped by beta 0.29, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DRGEM Corporation that is -12.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has DRGEM Corporation (263690) delivered so far?
Over the past 5 years revenue at DRGEM Corporation grew -0.7 % a year. The price currently implies free-cash-flow growth of -12.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DRGEM Corporation (263690) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DRGEM Corporation (-12.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DRGEM Corporation (263690)?
The free-cash-flow yield on the price is 13.60 %: that much free cash flow DRGEM Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DRGEM Corporation (263690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DRGEM Corporation it is 12,649 KRW per share (as of Nov 9, 2026), against a price of 4,870 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DRGEM Corporation stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 263690 trades below its calculated fair value: price 4,870 KRW, fair value 12,649 KRW, a gap of about +160% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 263690?
No. The price is what the market pays today (4,870 KRW); the fair value is what the company's own numbers justify (12,649 KRW). For DRGEM Corporation the two are 7,779 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DRGEM Corporation worth?
The market values DRGEM Corporation at about 53.1B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 4,870 KRW; our models calculate a fair value of 12,649 KRW per share.
What do the bullish and bearish scenarios say about 263690?
Our models span a range for DRGEM Corporation: cautious scenario 8,560 KRW, base 12,649 KRW, optimistic 17,110 KRW per share (as of Nov 9, 2026, price 4,870 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 263690?
DRGEM Corporation trades at a price-to-earnings ratio of 4.4 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 12,649 KRW is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings: 10.0. Other multiples: P/B 0.6, P/S 0.5, EV/EBITDA 3.6.
How solid is the balance sheet of DRGEM Corporation (263690)?
Balance-sheet figures for DRGEM Corporation (as of Nov 9, 2026): return on equity 13.3%, debt of 0.10 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 263690 from its 52-week high?
DRGEM Corporation trades at 4,870 KRW, about 16% below its 52-week high of 5,770 KRW and 3% above the low of 4,750 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 12,649 KRW is for.
Which stocks are comparable to DRGEM Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DRGEM Corporation stock attractive at the current price?
The data as of Nov 9, 2026: price 4,870 KRW, calculated fair value 12,649 KRW (+160%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 263690 calculated?
We run DRGEM Corporation through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 12,649 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DRGEM Corporation currently trades 62% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DRGEM Corporation (263690)?
The closing price on Nov 6, 2026 was 4,870 KRW. Our model-based fair value is 12,649 KRW, about +160% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DRGEM Corporation right now?
The price is below even our cautious bear case (8,560 KRW). The market is more pessimistic than our downside scenario. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (8,560 KRW to 17,110 KRW) leaves room in how you read the outcome.
Key figures of DRGEM Corporation
How large is the market capitalisation of DRGEM Corporation (263690)?
The market capitalisation of DRGEM Corporation is 53.1B KRW (≈ $39.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DRGEM Corporation (263690)?
The price-to-sales ratio of DRGEM Corporation is 0.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DRGEM Corporation (263690)?
Earnings per share at DRGEM Corporation are 1,127 KRW (price ÷ EPS = P/E 4.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DRGEM Corporation (263690)?
The dividend yield of DRGEM Corporation is 3.7% (payout 15.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DRGEM Corporation (263690)?
The net margin of DRGEM Corporation is 11.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DRGEM Corporation (263690)?
The return on equity (ROE) of DRGEM Corporation is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DRGEM Corporation (263690)?
On an EBIT basis the return on assets of DRGEM Corporation is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DRGEM Corporation (263690)?
The operating margin of DRGEM Corporation is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DRGEM Corporation (263690)?
Revenue at DRGEM Corporation is growing +10.0% versus a year earlier (3y avg −2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DRGEM Corporation (263690)?
Earnings per share at DRGEM Corporation are growing +295% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch DRGEM Corporation in the live analysis
One click puts DRGEM Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026